A carregar...
Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine‐threonine kinases. However, Sorafenib is expensive, and clinical experience shows that it is not an effective treatment for many patients. Previous study has demonstrated that phosphorylated...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5727337/ https://ncbi.nlm.nih.gov/pubmed/29030911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1228 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|